Media stories about Nightstar Therapeutics (NASDAQ:NITE) have trended somewhat positive this week, according to Accern. The research group rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Nightstar Therapeutics earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned news articles about the company an impact score of 47.5463561771927 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Several research firms recently issued reports on NITE. BMO Capital Markets began coverage on Nightstar Therapeutics in a research report on Monday, October 23rd. They set an “outperform” rating and a $30.00 price target on the stock. Leerink Swann assumed coverage on Nightstar Therapeutics in a research report on Monday, October 23rd. They issued an “outperform” rating and a $25.00 target price on the stock. Wedbush assumed coverage on Nightstar Therapeutics in a research report on Monday, October 23rd. They issued an “outperform” rating and a $19.00 target price on the stock. Finally, Jefferies Group assumed coverage on Nightstar Therapeutics in a research report on Monday, October 23rd. They issued a “buy” rating and a $25.00 target price on the stock.
Shares of Nightstar Therapeutics (NITE) traded down $0.63 during midday trading on Tuesday, reaching $13.12. The company’s stock had a trading volume of 17,000 shares, compared to its average volume of 71,034. Nightstar Therapeutics has a 1 year low of $11.99 and a 1 year high of $24.93.
Nightstar Therapeutics Company Profile
Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases.
Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.